Engineering Microbiome-Based Inhaled Therapies for Respiratory Diseases
- Addressing the complexities of selecting the right bacterial chassis for inhaled microbiome-based therapies to prevent rapid clearance by the immune system and respiratory physiology
- Exploring Pulmobiotics’ approach to engineering bacteria to produce human proteins like cytokines and interleukins to stimulate targeted immune responses in conditions like lung cancer
- Highlighting Pulmobiotics’ innovative use of microbiome-derived bacteria, such as their Mycoplasma pneumoniae-based candidate, to treat infectious diseases and disrupt biofilms in combination with standard antibiotics